Abstract

Botanical products have been increasingly popular in topical therapies for melasma, as presumed safer and milder than fully synthetic products. Although the efficacy of different topical botanicals has recently been substantiated through randomized controlled trials (RCTs), there is a lack of sufficiently pooled evidence on their efficacy and safety for the treatment of melasma. Herein, a systematic review and meta-analysis was conducted on the efficacy and safety of topical botanical products for the treatment of melasma, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). All RCTs on the use of topical botanical products for the treatment of melasma in humans were included, except for trials enrolling pregnant patients. The primary outcome was Melasma Area and Severity Index (MASI) or its variation. The secondary outcomes included Mexameter® reading, melasma improvement evaluated by participants, and any reported adverse events (AEs). As a result, twelve eligible trials comprising 695 patients with melasma from 6 different countries were included. The topical botanical products contained active ingredients which varied among trials as follows: herb-derived molecule, extracts of a single herb, and extracts of compound herbs. Topical therapy with botanical products significantly improved melasma with a large effect on MASI reduction (SMD −0.79, 95% CI −1.14 to −0.44, p < 0.00001), and a moderate effect on Mexameter® reading reduction (SMD −0.52, 95% CI −0.81 to 0.23, p = 0.0005), when compared with placebo. It also showed a similar improvement of melasma with a better safety profile (RR 0.37, 95% CI 0.15–0.88, p = 0.02), when compared with active-comparators. Botanical products were well-tolerated across studies, with no serious AEs reported. Despite the limitations such as small sample size, short duration of follow up and varied botanical products, this work still represents the best level of evidence currently available on topical use of botanical products on melasma. Moreover, it should be noted that more well-designed studies are needed before recommending topical botanical products as a viable treatment option for melasma.Systematic Review RegistrationPROSPERO, identifier: CRD42021256328.

Highlights

  • Melasma is an acquired hyperpigmentation disorder characterized by the appearance of abnormal melanin deposits in different layers of skin, especially the face and neck [1]

  • Our meta-analysis demonstrated that there was significant benefit associated with the use of botanical products in Mexameter R reading when compared with placebo, and no difference when compared with active-comparators

  • Botanical products have been increasingly popular in topical therapies for melasma, and many randomized controlled trials (RCTs) have been conducted to evaluate their efficacy

Read more

Summary

Introduction

Melasma is an acquired hyperpigmentation disorder characterized by the appearance of abnormal melanin deposits in different layers of skin, especially the face and neck [1]. The physiological and psychological effects of melasma have a considerable negative impact on the quality of life of affected individuals. This distressing condition is exacerbated by the therapeutic challenge due to its refractory and recurrent nature [3, 10]. Topical therapy with photoprotection and lightning products is still the mainstay for the treatment of melasma. Among these products, hydroquinone (HQ) has been used as the benchmark for decades, especially in epidermal melasma [3]. No consensus has been reached on their robust efficacy for melasma, let alone the accompanied AEs, namely, postinflammatory dyspigmentation, scarring, and venous thromboembolism [14]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call